|
Press Releases
December 2, 2003
Provectus Pharmaceuticals Announces Company Financing
KNOXVILLE, Tenn., Dec. 2 /PRNewswire/ -- Provectus Pharmaceuticals, Inc.(OTC Bulletin Board:
PVCT -
News)
announces that it has completed unsecured financing for the company of $500,000.
The total financing to the company would be $1.1 million after all warrants have
been converted. The financing was obtained from a group of accredited investors.
Read the complete article here.
November 18, 2003
Provectus to Advance Development of PH-10 for Treatment of Psoriasis
KNOXVILLE, Tenn.--November 18, 2003–-Provectus Pharmaceuticals, Inc.(BULLETIN BOARD:
PVCT - News)
announced today that the Company has an active IND (Investigational New Drug) application for PH-10
drug therapy with the FDA for Psoriasis.
Provectus Pharmaceuticals has completed a successful HUMAN pre-clinical trial in Europe and a number of Phase I
trials in the US. Provectus Psoriasis drug, PH-10, is now ready for Phase II/III HUMAN studies.
Psoriasis is a chronic disease and represents a market opportunity of over $1 billion.
Read the complete article here.
November 18, 2003
Provectus Pharmaceuticals, Inc. Aggressively Correcting Erroneous Reports of Large
Increase in Number of Free Trading Common Shares
KNOXVILLE, Tenn., Nov. 18 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals (OTC Bulletin Board:
PVCT -
News)
announced today that the Company is aggressively working to correct
erroneous reporting, by individuals, of the increase in the number
of free-trading common shares. Reports have been circulated that as
many as 1,593,752 more shares have been converted from restricted
to free trading shares since September 24, 2003. This number is not
correct. Examination of correct SEC filings currently available to
the company (Form 144) indicate that between September 24, 2003 and
November 17, 2003, only 283,752 shares have been converted from
restricted to free trading shares by shareholders.
Read the complete article here.
July 24, 2003
Provectus Pharmaceuticals Announces That Pure-ific Antibacterial
Hand Spray Kills Viruses in Laboratory
KNOXVILLE, Tenn.--(BUSINESS WIRE)--July 24, 2003--Provectus Pharmaceuticals, Inc.(OTC Bulletin Board:
PVCT -
News)
announced today that tests conducted in the company's laboratory indicate that
its Pure-ific(TM) Hand Spray can kill viruses when sprayed on inanimate surfaces.
Read the complete article here.
June 19, 2003
Provectus Pharmaceuticals Announces Distribution Agreement with Kevork Instruments
for Mexico and Central America
KNOXVILLE, Tenn.--June 19, 2003–-Provectus Pharmaceuticals, Inc.(BULLETIN BOARD:
PVCT - News)
today announced an international distribution agreement for its antibacterial
hand cleanser with Kevork Instruments of Monterrey, Mexico. Kevork will be the
exclusive distributor of Provectus' Pure-ific(TM) antibacterial hand spray in
Mexico and Central America.
Read the complete article here.
May 13, 2003
Provectus Pharmaceuticals Announces International Launch of Pure-ific Antibacterial Hand Spray
KNOXVILLE, Tenn.--May 13, 2003–-Provectus Pharmaceuticals, Inc.(OTC Bulletin Board:
PVCT - News)
announced today that Pure-ific(TM) antibacterial hand spray is now available for
sale to consumers.
Read the complete article here
|
